ClinicalTrials.gg
Active, not recruitingNCT06899061Updated Oct 1, 2026

Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of Saruparib

A Phase 1 interventional study of Saruparib and Digoxin in Advanced Solid Malignancies, sponsored by AstraZeneca. Active, not recruiting at 4 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by AstraZeneca · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
41
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

A Phase I modular study to assess the effect of oral saruparib on other treatments in patients with advanced solid malignancies.

Read the detailed description

Module 1 of the study is a Phase I, open-label study to assess the effects of saruparib on the PK of substrates digoxin (P-gp), furosemide (OAT1/3), metformin hydrochloride (OCT2/MATE1/2K), and rosuvastatin (OATP1B1/3) in participants with advanced solid malignancies.

Module 2 of the study is a Phase I, open-label, 4-treatment period, multi-centre, relative bioavailability, PPI effect, randomised, crossover study of saruparib tablets manufactured using a direct compression (DC) process in participants with advanced solid malignancies.

Module 1 of the study will include:

  • A Screening period of 28 days prior to Day 1.
  • Period 1: a single dose of a cocktail of substrates (digoxin, furosemide, metformin hydrochloride, and rosuvastatin) on Day 1.
  • A washout period of 1 to 3 days between Period 1 and Period 2.
  • Period 2: continuous dosing of saruparib from Day 1 to Day 9. On Day 5 saruparib will be administered in combination with the cocktail of substrates.
  • Period 3: a dose of saruparib per day for up to 3 cycles of 28 days each.
  • An End of Study visit up to 3 days after the last dose in Period 3.

Module 2 of the study will include:

  • A Screening period of 28 days prior to Day 1.
  • Period 1 and Period 2: a single dose of roller compaction (RC) or DC saruparib.
  • Period 3: from Day 1 to 3, two doses of rabeprazole per day. On Day 4, a dose of rabeprazole followed by DC saruparib.
  • A washout period of at least 3 days between Period 1 and Period 3, and between Period 2 and Period 3.
  • Period 4: a single dose of RC saruparib for up to 3 cycles.
  • An End of Study visit up to 3 days after the last dose in Period 4.
02

Conditions studied

  • Advanced Solid Malignancies

Keywords

  • Single-stranded DNA
  • Poly(ADP-ribose) polymerase 1
  • Transporter substrates
  • Pharmacokinetics
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,504 studies on the registry; 274 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants with documented evidence of locally advanced unresectable or solid tumours, excluding lymphoma, who have exhausted standard of care options (or for which no standard therapies exist) and may be suitable for saruparib monotherapy treatment in the opinion of the investigator.
  2. Adequate organ and marrow function (in the absence of transfusions or growth factor support within 28 days prior to enrolment).
  3. An PS: 0 to 1 with no deterioration within 1 week prior to the screening visit.
  4. ≥ 12 weeks.

Exclusion criteria

Exclusion Criteria:

  1. Evidence of active and uncontrolled and/or . Screening for hepatitis B and hepatitis C is not required, criteria is based on medical history.
  2. Participants with controlled need to meet the following criteria (screening for HIV is not required, criteria are based on medical history):

    1. Undetectable viral RNA load less than 400 copies/mL in the last 4 weeks prior to first dose of study intervention.
    2. of ≥ 350 cells/μL.
    3. No history of acquired immunodeficiency syndrome-defining opportunistic infection within the past 12 months, and stable on the same anti-HIV medications for at least 6 months. Screening for HIV is not required.
  3. Any other evidence of diseases, such as severe or uncontrolled systemic diseases or active uncontrolled infections, including but not limited to uncontrolled major seizure disorder, active bleeding diseases, superior vena cava syndrome, or history of allogenic organ transplant
  4. Active tuberculosis infection
  5. Any of the following cardiac criteria:

    1. Mean resting > 470 ms obtained from triplicate ECGs performed at screening and averaged. At each timepoint at which triplicate are required, 3 individual ECG tracings should be obtained in succession, no more than 2 minutes apart. The full set of triplicates should be completed within 5 minutes.
    2. Any factors that increase the risk of QT prolongation, shortening or risk of arrhythmic events such as hypokalaemia, congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death under 40 years of age in an immediate family member.
  6. History of arrhythmia (multifocal premature ventricular contractions, bigeminy, trigeminy, ventricular tachycardia), which is symptomatic or requires treatment ( Grade 3), symptomatic or uncontrolled atrial fibrillation despite treatment, or asymptomatic sustained ventricular tachycardia. Participants with atrial fibrillation controlled by medication or arrhythmias controlled by pacemakers may be permitted if deemed medically safe by the investigator.
  7. Other cardiovascular diseases with the exception of alopecia, and peripheral neuropathy; any unresolved toxicities from prior anticancer therapy greater than CTCAE Grade 1 at the time of study enrolment.
  8. Any known history of persisting (> 2 weeks) severe pancytopenia due to any cause ( \< 0.5 × 109/L or \< 50 × 109/L).
  9. Spinal cord compression, or for at least 4 weeks prior to start of study intervention unless asymptomatic and stable (ie, not requiring a dose of ≥ 10 mg for more than 2 weeks). A minimum of 2 weeks must have elapsed between the end of brain radiotherapy and signing the main study ICF.
  10. Participants with any known predisposition to bleeding (eg, active peptic ulceration, recent [within 6 months] haemorrhagic stroke, proliferative diabetic retinopathy).
  11. Participants with history of MDS/AML or with features suggestive of MDS/AML (as determined by prior diagnostic investigation). If there is no clinical MDS/AML suspicion, no specific screening for MDS/AML is required.
  12. nausea and vomiting, chronic GI diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption, distribution, metabolism, or excretion of study intervention.
  13. Known allergy or to study intervention or any of the of the study intervention.
  14. Any condition that, in the opinion of the investigator, would interfere with evaluation of the study intervention or interpretation of participant safety or study results.
  15. Past medical history of ILD, drug-induced ILD, radiation pneumonitis which required steroid treatment, or any evidence of clinically active ILD.
  16. Uncontrolled intercurrent illness within the last 12 months, including but not limited to, serious chronic GI conditions associated with diarrhoea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the participant to give written .

Module 1:

  1. Current or planned use of calcium channel blockers up to the end of Period 2.
  2. Current and/or regular use of any of the study interventions in the cocktail substrates that cannot be substituted.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
41 participants (actual)

Study arms

  • Active comparator
    Treatment Cohort (Module 1)

    Period 1: participants will receive a single oral dose of cocktail substrate (digoxin, furosemide, metformin hydrochloride, and rosuvastatin) on Day 1. Period 2: participants will receive a single dose saruparib from Day 1 to 9, and a single dose of cocktail substrate on Day 5 in combination with saruparib. Period 3: participants will receive a single oral dose of saruparib daily.

    Drug: Saruparib · Drug: Digoxin · Drug: Furosemide · Drug: Metformin Hydrochloride · Drug: Rosuvastatin

  • Active comparator
    Saruparib RC Cohort (Module 2)

    Period 1: participants will receive a single dose of RC saruparib. Period 2: participants will receive a single dose of DC saruparib. Period 3: participants will receive rabeprazole twice daily from Day 1 to 3, and a single dose of rabeprazole prior to DC saruparib on Day 4. Period 4: participants will receive RC saruparib daily for up to 3 cycles.

    Drug: Saruparib · Drug: Rabeprazole

  • Active comparator
    Saruparib DC Cohort (Module 2)

    Period 1: participants will receive a single dose of DC saruparib. Period 2: participants will receive a single dose of RC saruparib. Period 3: participants will receive rabeprazole twice daily from Day 1 to 3, and a single dose of rabeprazole prior to DC saruparib on Day 4. Period 4: participants will receive RC saruparib daily for up to 3 cycles.

    Drug: Saruparib · Drug: Rabeprazole

Interventions

  • Module 1: Period 2: participants will receive saruparib orally once daily from Day 1 to Day 9. On Day 5 saruparib will be administered orally in combination with the cocktail of substrates. Period 3: participants will receive saruparib orally once daily for up to 3 cycles of 28 days each. Module 2: Period 1 and Period 2: participants will receive a single oral dose of DC or RC saruparib. Period 3: participants will receive an oral dose of rabeprazole twice daily from Day 1 to 3, and a single oral dose of rabeprazole prior to DC saruparib on Day 4. Period 4: participants will receive an oral dose of RC saruparib daily for 3 cycles.

  • DrugDigoxin

    Period 1: participants will receive a single oral dose of a cocktail of substrates (digoxin, furosemide, metformin hydrochloride, and rosuvastatin) on Day 1. Period 2: participants will receive a single oral dose of the cocktail of substrates in combination with saruparib on Day 5.

    Also known as: P-gp

  • Period 1: participants will receive a single oral dose of a cocktail of substrates (digoxin, furosemide, metformin hydrochloride, and rosuvastatin) on Day 1. Period 2: participants will receive a single oral dose of the cocktail of substrates in combination with saruparib on Day 5.

    Also known as: OCT2

  • DrugMetformin Hydrochloride

    Period 1: participants will receive a single oral dose of a cocktail of substrates (digoxin, furosemide, metformin hydrochloride, and rosuvastatin) on Day 1. Period 2: participants will receive a single oral dose of the cocktail of substrates in combination with saruparib on Day 5.

    Also known as: OAT1/3, MATE1/2K

  • DrugRosuvastatin

    Period 1: participants will receive a single oral dose of a cocktail of substrates (digoxin, furosemide, metformin hydrochloride, and rosuvastatin) on Day 1. Period 2: participants will receive a single oral dose of the cocktail of substrates in combination with saruparib on Day 5.

    Also known as: OATP1B1/3

  • DrugRabeprazole

    Period 3: Participants will receive two doses of rabeprazole per day from Day 1 to 3. On Day 4, participants will receive a dose of rabeprazole followed by DC saruparib.

06

What researchers measure

Primary outcomes

  1. Module 1: Area under plasma concentration-time curve from zero extrapolated to infinity (AUCinf) of digoxin, furosemide, metformin and rosuvastatin when dosed alone and in combination with saruparib

    To evaluate the effects of saruparib on the PK of substrates of human drug transporters digoxin, furosemide, metformin hydrochloride, and rosuvastatin in participants with advanced solid malignancies.

    Time frame: Period 1: Days 1 to 5. Period 2: Days 5 to 9

  2. Module 1: Area under the plasma concentration curve from zero to the last quantifiable concentration (AUClast) of digoxin, furosemide, metformin and rosuvastatin when dosed alone and in combination with saruparib

    To evaluate the effects of saruparib on the PK of substrates of human drug transporters digoxin, furosemide, metformin hydrochloride, and rosuvastatin in participants with advanced solid malignancies.

    Time frame: Period 1: Days 1 to 5. Period 2: Days 5 to 9

  3. Module 1: Maximum observed plasma (peak) drug concentration (Cmax) of digoxin, furosemide, metformin and rosuvastatin when dosed alone and in combination with saruparib

    To evaluate the effects of saruparib on the PK of substrates of human drug transporters digoxin, furosemide, metformin hydrochloride, and rosuvastatin in participants with advanced solid malignancies.

    Time frame: Period 1: Days 1 to 5. Period 2: Days 5 to 9

  4. Module 2: AUClast between DC and RC tablets of saruparib

    To assess the relative bioavailability of saruparib tablets manufactured using a DC process versus RC process under fasted conditions.

    Time frame: Period 1: Days 1 to 3. Period 2: Days 1 to 3

  5. Module 2: AUCinf between DC and RC tablets of saruparib

    To assess the relative bioavailability of saruparib tablets manufactured using a DC process versus RC process under fasted conditions.

    Time frame: Period 1: Days 1 to 3. Period 2: Days 1 to 3

  6. Module 2: Cmax between DC and RC tablets of saruparib

    To assess the relative bioavailability of saruparib tablets manufactured using a DC process versus RC process under fasted conditions.

    Time frame: Period 1: Days 1 to 3. Period 2: Days 1 to 3

  7. Module 2: AUClast of DC saruparib tablets in the presence and absence of rabeprazole relative to the RC tablet

    To evaluate the effect of rabeprazole on saruparib PK profile following the administration of saruparib DC tablets.

    Time frame: Period 3: Days 4 to 6

  8. Module 2: AUCinf of DC saruparib tablets in the presence and absence of rabeprazole relative to the RC tablet

    To evaluate the effect of rabeprazole on saruparib PK profile following the administration of saruparib DC tablets.

    Time frame: Period 3: Days 4 to 6

  9. Module 2: Cmax of DC saruparib tablets in the presence and absence of rabeprazole relative to the RC tablet

    To evaluate the effect of rabeprazole on saruparib PK profile following the administration of saruparib DC tablets.

    Time frame: Period 3: Days 4 to 6

Secondary outcomes

  1. Module 1: Time to reach peak or maximum observed concentration following drug administration (tmax) of digoxin, furosemide, metformin and rosuvastatin when administered alone and in combination with saruparib, in plasma

    To assess PK, safety and tolerability of saruparib following oral dosing.

    Time frame: Period 1: Days 1 to 5. Period 2: Days 5 to 9

  2. Module 1: Half-life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve (t1/2λz) of digoxin, furosemide, metformin and rosuvastatin when administered alone and in combination with saruparib, in plasma

    To assess PK, safety and tolerability of saruparib following oral dosing.

    Time frame: Period 1: Days 1 to 5. Period 2: Days 5 to 9

  3. Module 1: Apparent total body clearance of drug from plasma after extravascular administration (CL/F) of digoxin, furosemide, metformin and rosuvastatin when administered alone and in combination with saruparib, in plasma

    To assess PK, safety and tolerability of saruparib following oral dosing.

    Time frame: Period 1: Days 1 to 5. Period 2: Days 5 to 9

  4. Module 1: Volume of distribution (apparent) at steady state following extravascular administration (based on terminal phase) (Vz/F) of digoxin, furosemide, metformin and rosuvastatin when administered alone and in combination with saruparib, in plasma

    To assess PK, safety and tolerability of saruparib following oral dosing.

    Time frame: Period 1: Days 1 to 5. Period 2: Days 5 to 9

  5. Module 1: Area under concentration time curve in the dosing interval (AUCtau) of saruparib after multiple doses in plasma

    To assess PK, safety and tolerability of saruparib following oral dosing.

    Time frame: Period 2: Days 5 to 9

  6. Module 1: AUClast of saruparib after multiple doses in plasma

    To assess PK, safety and tolerability of saruparib following oral dosing.

    Time frame: Period 2: Days 5 to 9

  7. Module 1: Minimum blood plasma concentration reached during a dosing interval (Cmin) of saruparib after multiple doses in plasma

    To assess PK, safety and tolerability of saruparib following oral dosing.

    Time frame: Period 2: Days 5 to 9

  8. Module 1: Number of Adverse Events (AEs) and Serious Adverse Events (SAEs)

    To assess PK, safety and tolerability of saruparib following oral dosing.

    Time frame: From Screening (Day -28) to Follow up, up to 129 days

  9. Module 1: Cmax of saruparib after multiple doses in plasma

    To assess PK, safety and tolerability of saruparib following oral dosing.

    Time frame: Period 2: Days 5 to 9

  10. Module 1: CL/F of saruparib after multiple doses in plasma

    To assess PK, safety and tolerability of saruparib following oral dosing.

    Time frame: Period 2: Days 5 to 9

  11. Module 1: Vz/F of saruparib after multiple doses in plasma

    To assess PK, safety and tolerability of saruparib following oral dosing.

    Time frame: Period 2: Days 5 to 9

  12. Module 1: t1/2λz of saruparib after multiple doses in plasma

    To assess PK, safety and tolerability of saruparib following oral dosing.

    Time frame: Period 2: Days 5 to 9

  13. Module 1: tmax of saruparib after multiple doses in plasma

    To assess PK, safety and tolerability of saruparib following oral dosing.

    Time frame: Period 2: Days 5 to 9

  14. Module 2: Number of Adverse Events (AEs) and Serious Adverse Events (SAEs)

    To assess the safety and tolerability of saruparib.

    Time frame: From Screening (Day -28) to Follow up, up to 167 days

  15. Module 2: Cmax of saruparib via DC and RC tablets

    To compare the PK of saruparib manufactured using a DC process versus RC process in participants with advanced solid malignancies.

    Time frame: Period 1: Days 1 to 3. Period 2: Days 1 to 3

  16. Module 2: tmax of saruparib via DC and RC tablets

    To compare the PK of saruparib manufactured using a DC process versus RC process in participants with advanced solid malignancies.

    Time frame: Period 1: Days 1 to 3. Period 2: Days 1 to 3

  17. Module 2: t½λz of saruparib via DC and RC tablets

    To compare the PK of saruparib manufactured using a DC process versus RC process in participants with advanced solid malignancies.

    Time frame: Period 1: Days 1 to 3. Period 2: Days 1 to 3

  18. Module 2: λz of saruparib via DC and RC tablets

    To compare the PK of saruparib manufactured using a DC process versus RC process in participants with advanced solid malignancies.

    Time frame: Period 1: Days 1 to 3. Period 2: Days 1 to 3

  19. Module 2: CL/F of saruparib via DC and RC tablets

    To compare the PK of saruparib manufactured using a DC process versus RC process in participants with advanced solid malignancies.

    Time frame: Period 1: Days 1 to 3. Period 2: Days 1 to 3

  20. Module 2: Vz/F of saruparib via DC and RC tablets

    To compare the PK of saruparib manufactured using a DC process versus RC process in participants with advanced solid malignancies.

    Time frame: Period 1: Days 1 to 3. Period 2: Days 1 to 3

  21. Module 2: Cmax of saruparib via DC tablets in the presence of rabeprazole

    To compare the PK of saruparib manufactured using a DC process versus RC process in participants with advanced solid malignancies.

    Time frame: Period 3: Days 4 to 6

  22. Module 2: tmax of saruparib via DC tablets in the presence of rabeprazole

    To compare the PK of saruparib manufactured using a DC process versus RC process in participants with advanced solid malignancies.

    Time frame: Period 3: Days 4 to 6

  23. Module 2: t½λz of saruparib via DC tablets in the presence of rabeprazole

    To compare the PK of saruparib manufactured using a DC process versus RC process in participants with advanced solid malignancies.

    Time frame: Period 3: Days 4 to 6

  24. Module 2: λz of saruparib via DC tablets in the presence of rabeprazole

    To compare the PK of saruparib manufactured using a DC process versus RC process in participants with advanced solid malignancies.

    Time frame: Period 3: Days 4 to 6

  25. Module 2: CL/F of saruparib via DC tablets in the presence of rabeprazole

    To compare the PK of saruparib manufactured using a DC process versus RC process in participants with advanced solid malignancies.

    Time frame: Period 3: Days 4 to 6

  26. Module 2: Vz/F of saruparib via DC tablets in the presence of rabeprazole

    To compare the PK of saruparib manufactured using a DC process versus RC process in participants with advanced solid malignancies.

    Time frame: Period 3: Days 4 to 6

07

Study locations

4 sites
  • Research Site
    Sofia, 1618, Bulgaria
  • Research Site
    Chisinau, MD-2025, Moldova
  • Research Site
    Bucharest, 022338, Romania
  • Research Site
    Cluj-Napoca, 400015, Romania
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2025 to primary completion in Feb 2026, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2025
First posted
Mar 27, 2025
StartActual
Mar 25, 2025
Primary completionActual
Feb 3, 2026
CompletionEst.
May 19, 2028
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06899061
Lead sponsor
AstraZeneca
Collaborators
Parexel
Responsible party
Sponsor
First posted
Mar 27, 2025
Start date
Mar 25, 2025
Primary completion
Feb 3, 2026
Completion
May 19, 2028 (estimated)
Last update
Oct 1, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: AZD5305 · Furosemide

Start the discussion